Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

Bicycle Therapeutics targets innovative cancer treatments with potential, like zelenectide pevedotin. Read here for an ...

Enriqueta Felip, MD, PhD, discusses the 3475A-D77 trial of subcutaneous pembrolizumab vs intravenous pembrolizumab plus chemotherapy in metastatic NSCLC.

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in ...

An April 6 article in the WaPo, one of the most recent as the NIH undergoes administrative changes, claims, “A big step forward in cancer therapy has been slowed by layoffs and ...

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more ...